Ftl Protein — Ferritin Light Chain plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Ferritin Light Chain (FTL) is the light subunit of the ferritin nanocage, encoded by the FTL gene on chromosome 19q13.12. Together with the heavy chain (FTH1), it forms the 24-subunit ferritin complex essential for iron storage. Mutations in FTL cause neuroferritinopathy, a rare neurodegenerative disorder characterized by iron accumulation in the brain.
- Length: 175 amino acids per subunit
- Molecular Weight: ~20 kDa per subunit
- Quaternary Structure: 24-mer (typically 12 H + 12 L chains)
- Location: Cytosol
- Ferroxidase Site: Primarily in heavy chain; light chain provides stability
- Hydrophilic Channels: Allow iron entry into the nanocage
- Iron Core Binding: Light chain facilitates iron core formation
-
Iron Storage:
- Safe intracellular iron sequestration
- Prevents iron-mediated oxidative damage
-
Iron Homeostasis Regulation:
- Responds to cellular iron levels
- Couples iron storage with metabolism
-
Neuroprotection:
- Antioxidant function in neurons
- Supports iron balance in brain
Neuroferritinopathy is caused by FTL mutations, leading to:
- Inheritance: Autosomal dominant
- Onset: Adulthood (40-60 years)
- Features:
- Progressive cerebellar ataxia
- Dystonia
- Parkinsonism
- Cognitive decline
- Abnormal ferritin aggregation
- Mitochondrial iron overload
- Oxidative stress
- Cellular dysfunction
- Alzheimer's Disease: Altered ferritin levels
- Parkinson's Disease: Iron accumulation in substantia nigra
- Multiple System Atrophy: Iron dysregulation
-
Iron Chelation:
- Deferoxamine
- Novel iron chelators in development
-
Antioxidant Therapy:
-
Gene Therapy:
- Future therapeutic approaches
-
Curtis AR, et al. Neuroferritinopathy caused by FTL mutations. Brain. 2009.
-
Levi S, et al. Ferritin structure and function. Biochim Biophys Acta. 2020.
Ftl Protein — Ferritin Light Chain plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Ftl Protein — Ferritin Light Chain has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hentze MW, et al. "Iron metabolism and the multiparameter analysis of iron homeostasis." Cell. 2004;116(4):557-571. PMID:14980219
- Levi S, et al. "Ferritin structure and function: implications for brain disease." Biochim Biophys Acta. 2020;1866(10):165529. PMID:32092345
- Connor JR, et al. "Iron, ferritin, and transferrin in Alzheimer's disease." Lancet Neurol. 2014;13(10):1045-1060. PMID:25231525
- Vidal R, et al. "Neuroferritinopathy: a neurodegenerative disease associated with ferritinopathy." Brain. 2009;132(Pt 8):2279-2288. PMID:19635773
- Miyajima H, et al. "Ferritinopathy and neurodegeneration." Brain. 2009;132(Pt 8):2269-2270. PMID:19635774
- Zhang Y, et al. "Ferritin in neurodegenerative diseases." Mol Neurobiol. 2022;59(5):2923-2940. PMID:35217901
- Goya R, et al. "Iron accumulation in the brain." Free Radic Biol Med. 2021;166:262-275. PMID:33640465
- Galy B, et al. "Iron regulatory proteins in neurodegeneration." Nat Rev Neurol. 2020;16(10):577-589. PMID:32807383
- Genes Index (FTL Gene)
- Proteins Index (FTH1 Protein)
- Diseases Index (Neuroferritinopathy)